Actinium Pharmaceuticals financials
$1.14−3.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.0K | $0.00 | $81.0K | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $90.0K | $0.00 | $81.0K | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | — | 100.0% | 100.0% | — | — | — | — | — | — |
| Operating income | -$36.2M | -$42.1M | -$51.9M | -$34.1M | -$26.1M | -$22.4M | -$22.1M | -$23.8M | -$26.9M | -$26.8M |
| Net income | -$33.9M | -$38.2M | -$48.8M | -$33.0M | -$24.8M | -$22.2M | -$21.9M | -$23.7M | -$26.6M | -$24.3M |
| Net margin | −37652.2% | — | −60269.1% | −3205.5% | — | — | — | — | — | — |
| Diluted EPS | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | $-1.83 | $-4.40 | $-6.60 | $-12.00 | $-15.00 |
| EBITDA | -$36.1M | -$41.9M | -$51.7M | -$33.4M | -$25.6M | -$21.9M | -$21.7M | -$23.8M | -$26.9M | -$26.8M |
| Operating cash flow | -$24.6M | -$33.1M | -$47.3M | $8.6M | -$20.9M | -$21.6M | -$21.5M | -$20.6M | -$21.6M | -$20.8M |
| Free cash flow | -$24.7M | -$33.1M | -$47.5M | $8.3M | -$21.0M | -$21.9M | -$21.5M | -$20.7M | -$21.6M | -$20.8M |
| Diluted shares | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | 12.1M | 5.0M | 3.5M | 2.2M | 1.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.0M | $72.9M | $76.7M | $108.9M | $77.8M | $63.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $11.0K | $20.0K | $30.0K | $10.1M | $65.0K | $151.0K |
| Total assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M | $66.4M |
| Total liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M | $5.1M |
| Shareholders' equity | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M | $61.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology